dsDNA

Benzene has this wonderful habit of intercolating into dsDNA and causing strand breaks — nasty nasty business.

The Volokh Conspiracy » The Parked Mustang Test of Environmental Progress 2010

Benzene has this wonderful habit of intercolating into dsDNA and causing strand breaks — nasty nasty business.

The Volokh Conspiracy » The Parked Mustang Test of Environmental Progress 2010

The genetic material can be dsRNA, ssDNA, or dsDNA between 5 and 500 kilo base pairs long with either circular or linear arrangement.

Cloverfield Haiku Contest Dennis 2007

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of CMV in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections.

unknown title 2011

The company's lead candidate, CMX001, is a broad spectrum, oral antiviral agent being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA dsDNA viruses, such as herpesviruses, adenoviruses, and orthopoxviruses.

unknown title 2011

To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols, including over 350 individuals who have received CMX001 under Emergency Investigational New Drug Applications EINDs or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there are no other therapeutic options.

unknown title 2011

Reduction in anti-dsDNA of 29.4% at Week 52 and 63.0% at

Business Wire Travel News 2010

Among patients who were positive for anti-double-stranded DNA autoantibodies (anti-dsDNA) at baseline, a significantly greater median percent reduction in anti-dsDNA was observed among patients in the belimumab treatment groups vs. the placebo group, with reductions observed by

Business Wire Travel News 2010

The Phase 3 development program for belimumab included two double-blind, placebo-controlled, multi-center Phase 3 superiority trials - BLISS-52 and BLISS-76 - to evaluate the efficacy and safety of belimumab plus standard of care, versus placebo plus standard of care, in seropositive (HEp-2 ANA ≥ 1: 80 and/or anti-dsDNA ≥ 30 IU/mL) patients with SLE.

Business Wire Travel News 2010

At Week 76, the median percent reduction in anti-dsDNA was 49.5% for belimumab 10 mg/kg, 43.3% for belimumab 1 mg/kg, and

Business Wire Travel News 2010